Cargando…
Safety and effectiveness of 4-week therapy with aceclofenac controlled release once a day
Aceclofenac controlled-release (CR) is a once-a-day tablet with 200 mg of aceclofenac, and is bioequivalent to conventional aceclofenac. However, its safety in humans has not been well studied in Korea. Therefore, we aimed to evaluate the overall incidence and patterns of adverse events (AEs), the e...
Autores principales: | Jeong, Ju-cheol, Chung, Yoon Hee, Park, Taejun, Park, Seung Yeon, Jung, Tae Woo, Abd El-Aty, A. M., Bang, Joon Seok, Jeong, Ji Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530112/ https://www.ncbi.nlm.nih.gov/pubmed/36192565 http://dx.doi.org/10.1038/s41598-022-20633-6 |
Ejemplares similares
-
Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets
por: Kim, Ju-Young, et al.
Publicado: (2015) -
Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study
por: Moon, Young-Wan, et al.
Publicado: (2014) -
The Suppressive Effect of Leucine-Rich Glioma Inactivated 3 (LGI3) Peptide on Impaired Skin Barrier Function in a Murine Model Atopic Dermatitis
por: Kim, Ui Seok, et al.
Publicado: (2020) -
Ginsenoside Rb3 ameliorates podocyte injury under hyperlipidemic conditions via PPARδ- or SIRT6-mediated suppression of inflammation and oxidative stress
por: Oh, Heeseung, et al.
Publicado: (2023) -
Development and Evaluation of Pharmacosomes of Aceclofenac
por: Semalty, A., et al.
Publicado: (2010)